Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAPK1 | P28482 | 1/20 | 0.78 |
| ▸ | HTR7 | P34969 | 5/20 | 0.67 |
| ▸ | DRD4 | P21917 | 4/20 | 0.66 |
| ▸ | DRD2 | P14416 | 3/20 | 0.66 |
| ▸ | DRD3 | P35462 | 2/20 | 0.66 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.64 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.61 |
| ▸ | LMNA | P02545 | 1/20 | 0.61 |
| ▸ | HTT | P42858 | 1/20 | 0.61 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.61 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.60 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL9225440 | 0.88 | MAPK1 (0.81) | MAPK1HTR7DRD4DRD2DRD3 | |
| SCHEMBL9720699 | 0.87 | HTR7 (0.65) | MAPK1HTR7DRD4DRD2DRD3 | |
| SCHEMBL19561754 | 0.87 | MAPK1 (0.80) | MAPK1HTR7DRD4DRD2DRD3 | |
| SCHEMBL6031726 | 0.87 | MAPK1 (0.80) | MAPK1HTR7DRD4DRD2DRD3 | |
| SCHEMBL6031061 | 0.87 | MAPK1 (0.80) | MAPK1HTR7DRD4DRD2DRD3 | |
| SCHEMBL18177886 | 0.87 | MAPK1 (1.00) | MAPK1HTR7DRD4DRD2DRD3 | |
| Bromide SCHEMBL6575673 | 0.86 | MAPK1 (0.78) | MAPK1HTR7DRD4DRD2DRD3 | |
| SCHEMBL9720708 | 0.85 | DRD4 (0.73) | MAPK1HTR7DRD4DRD2DRD3 | |
| SCHEMBL9720648 | 0.85 | HTR7 (0.70) | MAPK1HTR7DRD4DRD2DRD3 | |
| SCHEMBL9720726 | 0.85 | KDM4E (0.79) | MAPK1HTR7DRD4DRD2DRD3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20200071735-A1 | Compounds for Increasing Lipid Synthesis and Storage | WASE, NISHIKANT | 2020-03-05 | — | — | US | disclosed |
| US-20200071735-A1 | Compounds for Increasing Lipid Synthesis and Storage | WASE, NISHIKANT | 2020-03-05 | — | — | US | disclosed |
| US-10351883-B2 | Compounds for increasing lipid synthesis and storage | NUTECH VENTURES (US) | 2019-07-16 | — | — | US | disclosed |
| US-10351883-B2 | Compounds for increasing lipid synthesis and storage | NUTECH VENTURES (US) | 2019-07-16 | — | — | US | disclosed |
| US-20160312253-A1 | Compounds for Increasing Lipid Synthesis and Storage | INVITROGEN CORPORATION | 2016-10-27 | — | — | US | disclosed |
| US-20160312253-A1 | Compounds for Increasing Lipid Synthesis and Storage | INVITROGEN CORPORATION | 2016-10-27 | — | — | US | disclosed |
| US-20160312253-A1 | Compounds for Increasing Lipid Synthesis and Storage | INVITROGEN CORPORATION | 2016-10-27 | — | — | US | disclosed |
| US-5142052-A | Cationic effect-driven carbinol/amine reaction | LABORATOIRES SYNTEX (FR) | 1992-08-25 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20160312253-A1 | Compounds for Increasing Lipid Synthesis and Storage | FASN, LIPC, SREBF2 | MAPK1 3804/4885HTR7 4140/4885DRD4 3838/4885 |
| US-10351883-B2 | Compounds for increasing lipid synthesis and storage | FASN, LIPC, SREBF2 | MAPK1 3804/4885HTR7 4140/4885DRD4 3838/4885 |
| US-20200071735-A1 | Compounds for Increasing Lipid Synthesis and Storage | FASN, LIPC, SREBF2 | MAPK1 3804/4885HTR7 4140/4885DRD4 3838/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.